Dianthus Therapeutics Inc. (87E)
Munich
Closed
Aug 24, 2026
Day's Range
94.5052 wk Range
19.90Overview - 87E - Dianthus Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
-49.70M
P/E (Trailing)
‪-22.50‬
PEG Ratio
‪-9.90‬
Price / Book
‪4.51‬
EV / EBITDA
‪0.27‬
Profitability
Operating Margin
‪-8,739.34%‬
Return on Assets
‪-30.57%‬
Return on Equity
‪-32.90%‬
Ownership
Shares Outstanding
54.79M
Price stats
50-Day Avg
‪86.99‬
200-Day Avg
‪62.90‬
Peers - 87E - Dianthus Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- 87EMunichDianthus Therapeutics Inc.+78.62%52-week change-22.50P/E (Trailing)—Profit Margin
- 0QFMunichModerna, Inc.+81.73%52-week change25.19P/E (Trailing)‪-141.42%‬Profit Margin
- 4E2MunichRelmada Therapeutics Inc.+86.82%52-week change-2.80P/E (Trailing)—Profit Margin
- 42ZMunichRevolution Medicines Inc.+82.82%52-week change-30.32P/E (Trailing)—Profit Margin
- 5JA1MunichSprint Bioscience AB+82.07%52-week change0.28P/E (Trailing)‪92.17%‬Profit Margin
- B9B9P0MunichNovabay Pharmaceuticals Inc. R+80.00%52-week change-0.01P/E (Trailing)—Profit Margin
- 5NRMunichNanobiotix S.A.+77.80%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 87E - Dianthus Therapeutics Inc.
About
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It designs and delivers novel monoclonal antibodies and biologics with enhanced selectivity, potency, and dosing convenience…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
